Innoviva (INVA) Income from Continuing Operations (2010 - 2026)
Innoviva (INVA) posted Income from Continuing Operations of 186595000.0 for Q1 2026, up 1191.71% on a QoQ basis from 17092000.0 in Q4 2025, and up 500.51% year-over-year from 31072599.77 in Q1 2025.
Innoviva (INVA) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Innoviva's Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 186595000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 500.51% year-over-year to 186595000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 340217000.0 (up 463.02% YoY) and the FY2025 annual result came in at 326862000.0, up 1329.41% from the prior year.
- Income from Continuing Operations was 186595000.0 for Q1 2026 at Innoviva, up from 17092000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 288576000.0 in Q3 2022 and bottomed at 175827000.0 in Q4 2023.
- A 5-year average of 34909235.29 and a median of 21395000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations sank 2757.85% — and 2025, when it soared 3359.15%.
- Innoviva's Income from Continuing Operations stood at 15903000.0 in 2022, then sank by 1005.62% to 175827000.0 in 2023, then surged by 91.16% to 15539000.0 in 2024, then fell by 9.99% to 17092000.0 in 2025, then soared by 1191.71% to 186595000.0 in 2026.
- Business Quant data shows INVA's Income from Continuing Operations at 186595000.0 in Q1 2026, 17092000.0 in Q4 2025, and 107026000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Innoviva | 1.59 Bn | 983.20 Mn | 75.83 Mn | 186.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 186.60 Mn |
| Dec 31, 2025 | -17.09 Mn |
| Sep 30, 2025 | 107.03 Mn |
| Jun 30, 2025 | 63.69 Mn |
| Mar 31, 2025 | -46.59 Mn |
| Dec 31, 2024 | -15.54 Mn |
| Sep 30, 2024 | 3.09 Mn |
| Jun 30, 2024 | -34.69 Mn |
| Mar 31, 2024 | 36.52 Mn |
| Dec 31, 2023 | -175.83 Mn |
| Sep 30, 2023 | 118.19 Mn |
| Jun 30, 2023 | 1.31 Mn |
| Mar 31, 2023 | 34.84 Mn |
| Dec 31, 2022 | -15.90 Mn |
| Sep 30, 2022 | 288.58 Mn |
| Jun 30, 2022 | 21.40 Mn |
| Mar 31, 2022 | 37.86 Mn |
| Dec 31, 2021 | -44.88 Mn |
| Sep 30, 2021 | 323.19 Mn |
| Jun 30, 2021 | 110.85 Mn |